Inclusion Criteria:

- Male or female patients with newly diagnosed multiple myeloma (MM) requiring therapy
for whom stem cell transplantation is considered appropriate

- Normal left ventricular ejection fraction

- Able to give voluntary written informed consent

- Female patients agree to use acceptable method for contraception

Exclusion Criteria:

- Diagnosis of smoldering multiple myeloma (asymptomatic MM with absence of lytic bone
lesions)

- Renal insufficiency related to the monoclonal protein

- Diagnosis of Waldenström's disease

- Previous treatment for MM (excepting emergency use of a short course dexamethasone,
radiation received > 30 days before study enrolment, plasmapheresis for treatment of
clinically significant hyperviscosity syndrome > 30 days before trial enrolment)

- Major surgery within 30 days before entry

- Peripheral neuropathy or neuropathic pain Grade 2 or higher within 14 days of trial
enrolment

- Uncontrolled or severe cardiovascular disease (including myocardial infarction within
6 months prior to enrollment

- NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled
ventricular arrhythmias, clinically significant pericardial disease, cardiac
amyloidosis, or electrocardiographic evidence of acute ischemic or active conduction
system abnormalities)

- Other malignancy within the past 5 years prior to enrolment (except for non-active
basal cell or non-metastatic squamous cell carcinoma of the skin, cervical carcinoma
in situ or Stage 1 carcinoma of the cervix

- Known HIV seropositivity or active hepatitis A, B, or C infection

- Use of any investigational drug within 30 days prior to enrolment in the trial

- Medical or psychiatric condition that could interfere with trial participation

- History of hypersensitivity or allergic reaction attributable to compounds containing
boron, mannitol or doxorubicin.